The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
17 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,535,299 in first-year total cost, median $895,512.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-N (M1)]17
Most frequent institutions
- DANA-FARBER CANCER INST6
- BETH ISRAEL DEACONESS MEDICAL CENTER1
- BOSTON CHILDREN'S HOSPITAL1
- BROAD INSTITUTE, INC.1
- HARVARD MEDICAL SCHOOL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Annotating Cancer Biology through Non-Invasive Molecular Imaging1R35CA232130-01A1 | LEWIS, JASON S. | SLOAN-KETTERING INST CAN RESEARCH, NY | $1,077,600 | ZCA1 |
| 2019 | Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway1R35CA242461-01 | ECK, MICHAEL J | DANA-FARBER CANCER INST, MA | $1,068,000 | ZCA1 |
| 2019 | Precision microRNA medicine in cancer1R35CA232105-01A1 | SLACK, FRANK J. | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $1,050,000 | ZCA1 |
| 2019 | Making cancer precision medicine real: bottlenecks and opportunities1R35CA242457-01 | GOLUB, TODD R. | BROAD INSTITUTE, INC., MA | $1,024,290 | ZCA1 |
| 2019 | Tracking the evolution of breast cancer through single cell analyses of premalignant breast tissues from women at high risk for cancer development1R35CA242428-01 | BRUGGE, JOAN SIEFERT | HARVARD MEDICAL SCHOOL, MA | $1,017,000 | ZCA1 |
| 2019 | Role of the Epitranscriptome in Cancer1R35CA232115-01A1 | GREGORY, RICHARD I. | BOSTON CHILDREN'S HOSPITAL, MA | $931,087 | ZCA1 |
| 2019 | Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy1R35CA232109-01A1 | TING, JENNY P | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $925,890 | ZCA1 |
| 2019 | Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers1R35CA231945-01A1 | ROBERTS, THOMAS M | DANA-FARBER CANCER INST, MA | $925,398 | ZCA1 |
| 2019 | Identification of Novel Oncogenic Signaling Pathways using Viral Perturbations1R35CA232128-01A1 | DECAPRIO, JAMES A. | DANA-FARBER CANCER INST, MA | $895,512 | ZCA1 |
| 2019 | Deciphering the mechanism underlying BRCA1 breast cancer development1R35CA242143-01 | LIVINGSTON, DAVID MORSE | DANA-FARBER CANCER INST, MA | $845,095 | ZCA1 |
| 2019 | Reading mitochondrial apoptotic signaling to identify active cancer therapeutics1R35CA242427-01 | LETAI, ANTHONY G | DANA-FARBER CANCER INST, MA | $810,207 | ZCA1 |
| 2019 | Understanding the role of metabolism in cancer1R35CA242379-01 | VANDER HEIDEN, MATTHEW G. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $803,011 | ZCA1 |
| 2019 | Targeting High-Risk Lymphoid Neoplasms1R35CA231958-01A1 | WEINSTOCK, DAVID MARC | DANA-FARBER CANCER INST, MA | $798,668 | ZCA1 |
| 2019 | Mechanisms of regulated translation control in cancer and its therapeutic implications1R35CA242986-01 | RUGGERO, DAVIDE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $712,974 | ZCA1 |
| 2019 | Histidine phosphorylation as a new target for cancer therapy1R35CA242443-01 | HUNTER, TONY R. | SALK INSTITUTE FOR BIOLOGICAL STUDIES, CA | $614,254 | ZCA1 |
| 2019 | Mechanisms of DNA Homology-directed Genome Repair and Tumor Suppression1R35CA241801-01 | SUNG, PATRICK | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $546,102 | ZCA1 |
| 2019 | Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies1R35CA231997-01A1 | SAGE, JULIEN | STANFORD UNIVERSITY, CA | $490,211 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.